Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.
Neuronetics is developing a non-invasive medical technology to treat depression using Transcranial Magnetic Stimulation (TMS). Neuronetics was founded within The Innovation Factory in 2001.
OCERA THERAPEUTICS, INC., founded in January 2005 and headquartered in San Diego, CA., is a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases. Ocera's initial product candidate, AST-120, is an oral adsorbent marketed in Japan to treat patients with ch...
More >>
OCERA THERAPEUTICS, INC., founded in January 2005 and headquartered in San Diego, CA., is a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases. Ocera's initial product candidate, AST-120, is an oral adsorbent marketed in Japan to treat patients with chronic kidney disease. Ocera was co-founded by Dr. Eckard Weber of Domain Associates and Dr. Laurent Fischer.
<< Less
ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Denver, Colorado.
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Effective June 22, 2007, Transcept Pharmaceuticals, Inc. has a new name. The company name was changed from Transoral Pharmaceuticals, Inc. to Transcept Pharmaceuticals, Inc., emphasizing the company's business strategy to develop impro...
More >>
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Effective June 22, 2007, Transcept Pharmaceuticals, Inc. has a new name. The company name was changed from Transoral Pharmaceuticals, Inc. to Transcept Pharmaceuticals, Inc., emphasizing the company's business strategy to develop improved performance and new uses for proven CNS agents. Transcept is particularly focused on therapeutic agents of importance to psychiatrists and their patients. The Company has successfully completed its initial Phase 3 sleep laboratory study of low dose Intermezzo (sublingual zolpidem tartrate) in the treatment of insomnia as characterized by patients who awaken in the middle of the night and have difficulty returning to sleep. Transcept expects to begin the remaining Phase 3 Intermezzo outpatient study in the second quarter of 2007. Transcept is also pursuing the development of a low dose ondansetron/olanzapine combination product for the treatment of alcohol dependence. The Company anticipates that this therapeutic combination may also be useful in the treatment of other forms of addiction and other psychiatric conditions.
<< Less
based on 1 reviews Category : Health Sector : Healthcare Industry : Pharmaceuticals / Drugs Sub-Industry :
California
United States
Kanisa Pharmaceuticals (San Diego, CA) is a pharmaceutical company focused on the acquisition, development and commercialization of therapeutics in the field of oncology.
Restoration Robotics is an aesthetics company developing a robotic device to provide increased speed and precision in hair transplantation. The office-based device is capable of rapidly harvesting and implanting individual hairs minimally invasively, auto
Cardiomind is developing innovative small diameter delivery devices and stents potentially useful in treating a variety of neurological and cardiovascular disease conditions.
Radius is a privately held company that aims to offer the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
This page is accessible to a membership level higher than you. To improve your membership level you can try the following:
Review More Companies
Complete your profile
Improve your fanbase
Add/Edit more companies
Send a request to site admin at membership@chubbybrain.com requesting to upgrade your membership level. If your profile is eligible, your membership level will be upgraded and you will be notified.
Why can I not access this page?
This page is accessible to a membership level higher than you. To improve your membership level you can try the following:
Review More Companies
Complete your profile
Improve your fanbase
Add/Edit more companies
Send a request to site admin at membership@chubbybrain.com requesting to upgrade your membership level. If your profile is eligible, your membership level will be upgraded and you will be notified.
9,810 Investors 
